TY - JOUR
T1 - Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma
AU - Schleiss-Andreassen, Julie L.
AU - Kristensen, Elisabeth
AU - Frøding, Ligita Paskeviciute
AU - Stæhr, Estrid
AU - Høgdall, Claus
AU - Christiansen, Anne Pernille
AU - Høgdall, Estrid
AU - Schnack, Tine Henrichsen
PY - 2022/3
Y1 - 2022/3
N2 - Objective: To evaluate recurrence rates and risk factors of relapse in stage IA vulvar squamous cell carcinoma (VSCC) patients. Material and methods: Population-based prospectively collected data on stage IA VSCC was retrieved through the Danish Gynecological Cancer Database (DGCD) during 2011–2017. A central pathology review was performed on tumors from women with recurrent disease. Results: 62 women diagnosed and treated for stage IA VSCC were identified. Nine (14.5%) of the included cases relapsed within the observation period. The recurrences were in the vulva, groins or both in 5 (8.1%), 3 (4.8%) and 1 (1.6%) of the women, respectively. At central pathology review, including all recurrent cases (n = 9), 5 out of 21 reviewed patients were upstaged to stage IB due to depth of invasion >1 mm and two were downstaged to Carcinoma in situ. Two of the upstaged women developed an isolated groin recurrence and one an isolated vulvar relapse. After exclusion of the seven cases the overall recurrence rate decreased to 10.9% (n = 6). Among these cases (n = 55) resection margin <8 mm and tumor size were associated with cancer recurrence. Conclusion: Pathological assessment of stage IA VSCC (depth of invasion ≤1 mm) may be difficult. This may result in under-staging, which impact the choice of treatment and possibly the prognosis. This suggests a need for further clarification of the FIGO measurement and may require a more radical approach when it comes to treatment and groin exploration in stage IA VSCC. Resection margins <8 mm and tumor size were associated with relapse of the disease.
AB - Objective: To evaluate recurrence rates and risk factors of relapse in stage IA vulvar squamous cell carcinoma (VSCC) patients. Material and methods: Population-based prospectively collected data on stage IA VSCC was retrieved through the Danish Gynecological Cancer Database (DGCD) during 2011–2017. A central pathology review was performed on tumors from women with recurrent disease. Results: 62 women diagnosed and treated for stage IA VSCC were identified. Nine (14.5%) of the included cases relapsed within the observation period. The recurrences were in the vulva, groins or both in 5 (8.1%), 3 (4.8%) and 1 (1.6%) of the women, respectively. At central pathology review, including all recurrent cases (n = 9), 5 out of 21 reviewed patients were upstaged to stage IB due to depth of invasion >1 mm and two were downstaged to Carcinoma in situ. Two of the upstaged women developed an isolated groin recurrence and one an isolated vulvar relapse. After exclusion of the seven cases the overall recurrence rate decreased to 10.9% (n = 6). Among these cases (n = 55) resection margin <8 mm and tumor size were associated with cancer recurrence. Conclusion: Pathological assessment of stage IA VSCC (depth of invasion ≤1 mm) may be difficult. This may result in under-staging, which impact the choice of treatment and possibly the prognosis. This suggests a need for further clarification of the FIGO measurement and may require a more radical approach when it comes to treatment and groin exploration in stage IA VSCC. Resection margins <8 mm and tumor size were associated with relapse of the disease.
KW - Vulvar squamous cell carcinoma
KW - Stage IA
KW - Invasion depth
KW - Recurrence
KW - Interobserver agreement
KW - Interobserver agreement
KW - Invasion depth
KW - Recurrence
KW - Stage IA
KW - Vulvar squamous cell carcinoma
KW - Humans
KW - Risk Factors
KW - Margins of Excision
KW - Neoplasm Recurrence, Local/epidemiology
KW - Male
KW - Vulvar Neoplasms/pathology
KW - Carcinoma, Squamous Cell/pathology
KW - Female
KW - Retrospective Studies
KW - Neoplasm Staging
U2 - 10.1016/j.ygyno.2021.12.020
DO - 10.1016/j.ygyno.2021.12.020
M3 - Journal article
C2 - 34973843
SN - 0090-8258
VL - 164
SP - 543
EP - 549
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -